Back to Search
Start Over
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
- Source :
-
Haematologica [Haematologica] 2018 May; Vol. 103 (5), pp. 799-809. Date of Electronic Publication: 2018 Feb 08. - Publication Year :
- 2018
-
Abstract
- Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT , which confers resistance against imatinib. Clinical problems in systemic mastocytosis arise from mediator-related symptoms and/or organ destruction caused by malignant expansion of neoplastic mast cells and/or other myeloid cells in various organ systems. DCC-2618 is a spectrum-selective pan KIT and PDGFRA inhibitor which blocks KIT D816V and multiple other kinase targets relevant to systemic mastocytosis. We found that DCC-2618 inhibits the proliferation and survival of various human mast cell lines (HMC-1, ROSA, MCPV-1) as well as primary neoplastic mast cells obtained from patients with advanced systemic mastocytosis (IC <subscript>50</subscript> <1 μM). Moreover, DCC-2618 decreased growth and survival of primary neoplastic eosinophils obtained from patients with systemic mastocytosis or eosinophilic leukemia, leukemic monocytes obtained from patients with chronic myelomonocytic leukemia with or without concomitant systemic mastocytosis, and blast cells obtained from patients with acute myeloid leukemia. Furthermore, DCC-2618 was found to suppress the proliferation of endothelial cells, suggesting additional drug effects on systemic mastocytosis-related angiogenesis. Finally, DCC-2618 was found to downregulate IgE-mediated histamine release from basophils and tryptase release from mast cells. Together, DCC-2618 inhibits growth, survival and activation of multiple cell types relevant to advanced systemic mastocytosis. Whether DCC-2618 is effective in vivo in patients with advanced systemic mastocytosis is currently under investigation in clinical trials.<br /> (Copyright © 2018 Ferrata Storti Foundation.)
- Subjects :
- Aged
Aged, 80 and over
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism
Male
Mast Cells drug effects
Mast Cells metabolism
Mastocytosis, Systemic drug therapy
Mastocytosis, Systemic metabolism
Middle Aged
Mutation
Tumor Cells, Cultured
Cell Proliferation drug effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology
Mast Cells pathology
Mastocytosis, Systemic pathology
Protein Kinase Inhibitors pharmacology
Proto-Oncogene Proteins c-kit antagonists & inhibitors
Receptor, Platelet-Derived Growth Factor alpha antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 103
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 29439183
- Full Text :
- https://doi.org/10.3324/haematol.2017.179895